Warburg Pincus in talks to sell stake in SBI General Insurance, Bloomberg News reports
(Reuters) -U.S.-based private equity firm Warburg Pincus is in talks to sell its stake in State Bank of India's general insurance arm, Bloomberg News reported on Monday, citing people familiar with the matter.
Warburg Pincus is negotiating with Premji Invest, the investment unit of Indian billionaire Azim Premji, and SBI, the country's largest lender, to divest its 10% stake in SBI General Insurance, the report said.
The transaction could value SBI General Insurance at as much as $4.5 billion, Bloomberg News reported.
Reuters could not independently verify the report. Warburg Pincus, Premji Invest, and SBI did not immediately respond to Reuters' request for comment.
Premji Invest and a Warburg Pincus affiliate bought 16.01% and 9.99% interests in SBI General, respectively, in 2019, in a deal worth $432.38 million.
State Bank of India currently owns about 70% of SBI General Insurance.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Bloomberg
10 minutes ago
- Bloomberg
Goldman ICBC Wealth JV CEO Leaves Amid Growth Pains, Competition
Goldman Sachs Group Inc. 's top executive at its wealth venture with China's biggest bank has resigned, people familiar with the matter said, as foreign firms struggle to gain a foothold in the country's asset management market amid deepening economic strains. Alex Wang, chief executive officer of Goldman Sachs ICBC Wealth Management, is leaving after almost 15 years at Goldman's asset management affiliate in China, the people said, asking not to be identified because the matter isn't public. He is in discussions to join Nomura Holdings Inc. with a similar title to run its securities business, the people said, asking not to be identified.
Yahoo
19 minutes ago
- Yahoo
SoftBank's Founder Lays Out Vision to Be No. 1 in Artificial Superintelligence
TOKYO—SoftBank's founder wants to make his company the world leader in artificial superintelligence—a hypothetical form of AI that is smarter than humans—within the next 10 years. 'I am betting all in on the world of ASI,' SoftBank Group Chief Executive Masayoshi Son said at an annual shareholder meeting held in Tokyo on Friday. It's Known as 'The List'—and It's a Secret File of AI Geniuses It's a New Era for Capital One. Amex and Chase Are in Its Sights. It's Bulletproof, Fire-Resistant and Stronger Than Steel. It's Superwood. These Funds Are Yield Magicians. How Do They Do It? The 33-Year-Old Meat Heir Feeding America's Protein Obsession Son said that in the next decade, just a handful of companies will reap the benefits from the around 600 trillion yen, equivalent to $4.155 trillion, of profit that stands to be made from ASI. A key part of Son's strategy is strengthening the Japanese technology investment company's relationship with OpenAI. SoftBank will have invested up to $32 billion in OpenAI by the end of this year, the CEO said, making it one of the largest single investments ever made in a private company. In February, the two companies announced a plan for a joint venture to provide major Japanese companies with advanced enterprise AI called 'Cristal intelligence.' 'OpenAI will eventually go public and become the most valuable company on Earth,' Son said, expecting a listing to happen in the next few years. SoftBank, which has backed high-profile tech names such as Alibaba and Arm, has been stepping up its push into AI. Last July, it acquired U.K.-based AI chip maker Graphcore, and this year it announced the acquisition of U.S. semiconductor design company Ampere Computing in a $6.5 billion deal. Earlier this year, SoftBank and OpenAI announced a joint project called Stargate to build infrastructure for the ChatGPT maker. Database company Oracle and MGX, an investor backed by the United Arab Emirates, are also equity partners in the venture. The companies have pledged to invest up to $500 billion in Stargate over the next four years. SoftBank's investment plans have come under scrutiny as Japan tries to close a deal with the Trump administration, which is looking to fill a trade gap and invite more foreign investment into the U.S. Asked by a shareholder about his relationship with President Trump, Son emphasized the importance of working closely with the U.S. administration. 'America is the world's largest AI hub and the technical epicenter of this revolution,' Son said. 'America is where the greatest opportunities lie.' News Corp, owner of The Wall Street Journal and Dow Jones Newswires, has a content-licensing partnership with OpenAI. Write to Megumi Fujikawa at U.S. Economy Shrugs Off Trade War and Soldiers On California Gov. Newsom Sues Fox News for Defamation Historic Rebound Sends S&P 500 to New Highs Sanctioned Steelmaker Finds a Buyer for U.S., Canada Plants I Built an AI Career Coach. I've Never Had a Better Coach. Sign in to access your portfolio
Yahoo
19 minutes ago
- Yahoo
Mystery $33 Billion Medicine Fortune Collapses in Days
(Bloomberg) -- When Yat-Gai Au was worth $33 billion on paper, he wasn't in his Hong Kong office. Philadelphia Transit System Votes to Cut Service by 45%, Hike Fares US Renters Face Storm of Rising Costs Squeezed by Crowds, the Roads of Central Park Are Being Reimagined Mapping the Architectural History of New York's Chinatown US State Budget Wounds Intensify From Trump, DOGE Policy Shifts One week later, when his net worth plunged to $10.1 billion, he wasn't around either. Officers at the headquarters of Regencell Bioscience Holdings Ltd said both times that Au only takes short visits there, before turning away reporters. The firm, a Nasdaq-listed, Cayman Islands-incorporated traditional Chinese medicine company, occupies the whole 9th floor of a tower in Hong Kong's bustling Causeway Bay, including a reception area with a large table-tennis table. Little is still known about the tiny, money-losing company whose shares exploded 82,000% higher and suddenly made Au, its chief executive officer with an 86% stake, richer on paper than some of the city's tycoons like Li Ka-shing. The fleeting nature of its rip-roaring rally has captivated and mystified observers from the US to Hong Hong. Morning Brew, a popular business account on X, flagged its stock move and wondered: 'Is there something I'm missing?' Regulators in the US, which closely monitor wild swings in stock prices, might soon be asking the same question, according to experts. The Financial Industry Regulatory Authority, the watchdog for broker-dealers, has repeatedly warned that small, cheap stocks are more susceptible to fraud. These companies can be targets for pump-and-dump schemes in which fraudsters inflate the stock price and quickly sell their shares. The US Securities and Exchange Commission, meanwhile, has been increasingly wary about companies listed on US exchanges that are based overseas — and Regencell checks both boxes. The regulator on June 4 called on the public to weigh in on whether the agency needed to amend the definition of what's called a foreign private issuer, potentially limiting the number of companies that qualify for special status that lets them avoid filing quarterly financial reports or disclosing when executives buy or sell company shares. 'This is an example of very unusual movements in share prices,' said Richard Harris, founder and chief executive of Port Shelter Investment Management in Hong Kong. 'These movements could certainly trigger interest by investigators.' The SEC and Finra declined to comment on whether they were monitoring Regencell's moves. Finra's mission is to protect investors and safeguard market integrity, spokesperson Rita De Ramos said. 'In line with that mission, Finra continues to monitor the market for unusual trading activity, as part of our normal course of action.' Regencell didn't respond to emails and phone calls for comment on its stock performance and its founder's fortune. The company's shares have retreated 74% from their peak, shrinking Au's stake to about $8.6 billion as of June 26. Founded in 2014, Regencell's main line of business is marketing and licensing traditional treatments for ADHD and autism spectrum disorder developed by the founder's father, Sik-Kee Au. It has exclusive rights over his traditional medicinal formulas, trademarked under the name Brain Theory. The firm posted net losses of $4.4 million and $6.1 million, respectively, for the fiscal years ended June 2024 and 2023, according to filings. Its chief medical officer position has been vacant since the last doctor to hold the job resigned in 2022. The younger Au attended the Haas School of Business at the University of California, Berkeley and worked at Deutsche Bank AG in the late 1990s. He suffered from learning disorders and speech problems, had poor grades and an uncontrollable temper, according to a video post on the company's Instagram account. Regencell's mission is to 'improve and save lives using a natural and holistic TCM formula to treat ADHD and ASD,' according to the same video. The company's official Instagram account has more than half a million followers. BeOne Medicines Ltd., the largest healthcare firm listed in Hong Kong, has just over 2,500. Regencell built out a following with the help of social-media campaigns on the platform that offered free tickets for Taylor Swift concerts in the US and Asia. The company's second-largest shareholder is Digital Mobile Venture Ltd., a firm ultimately owned by Taiwan's Samuel Chen and his wife Fiona Chang. Chen was an investor whose early investments in Zoom Video Communications Inc. made him a fortune when the company's stock soared almost 1,500% during the pandemic. Chen, Chang and their children own a 55% stake in Taipei-based Polaris Group, a biotechnology company developing anti-cancer drugs. He's also the biggest shareholder of Sonix Technology Co., a provider of integrated circuits listed in Taipei. Bloomberg News received no reply to emails sent to Polaris and Sonix seeking comments from Chen. While monitoring for wild price swings used to be done manually, the SEC and Finra now have programs to automatically detect market anomalies, according to Erik Gordon, professor at the University of Michigan's Ross School of Business. They can also compel companies to share if they know why their stock price soared or crashed or whether insiders cashed in at the peak. The absence of profits or revenues at Regencell isn't an automatic red flag; plenty of early-stage pharmaceutical companies have similar finances, he said. On June 18, two men and a woman arrived at Regencell's Hong Kong office seeking information about treatment for ADHD and dementia. They said they read about the stock's surge before arriving. The visitors were also turned away. An employee said its staff were not doctors, and directed them to the company's website. 'Early stage pharma companies can jump from a dollar to four dollars in 90 seconds if there's some news about one of their drugs under development doing well in a clinical trial,' Gordon said. In this case, 'what's interesting is there's no news.' --With assistance from Dylan Sloan. (Adds stock decline since peak and Yat-Gai Au's stake in 11th paragraph.) America's Top Consumer-Sentiment Economist Is Worried How to Steal a House Inside Gap's Last-Ditch, Tariff-Addled Turnaround Push Apple Test-Drives Big-Screen Movie Strategy With F1 Luxury Counterfeiters Keep Outsmarting the Makers of $10,000 Handbags ©2025 Bloomberg L.P. Sign in to access your portfolio
